Insights

In a significant move for the UK's life sciences sector, BioNTech, renowned for its role in developing the Pfizer-BioNTech COVID-19 vaccine, has announced a £1 billion investment over the next decade.  

This paper is part of our Sustainability Insights series following the 2025 PING Conference on Sustainability - What must Pharma do now? - bringing you expert perspectives and practical takeaways from key discussions shaping the future of businesses looking to address the threats and opportunities of sustainability in the life sciences sector. Thanks to Hertfordshire Futures for their great support of PING yet again.

Over a month has passed since the 2024 PING conference, providing invaluable insights into the uptake of AI in Pharma, its transformational promise, and the accompanying risks and pitfalls. Below is a summary of our key takeaways.

For life sciences companies processing health or genetic data, useful lessons can be taken from the 23andMe data breach, which is back in the spotlight thanks to a joint investigation by the UK and Canadian data protection authorities.

The UK Government has recently allocated substantial funding of over £100 million to support five new quantum research hubs across the UK.

When a licensee entered into a trade mark licence for 25 years and decided five years in that they did not want to use the trade mark any more, they were still required to pay the large minimum royalties, the Court of Appeal has ruled.